T-DM1 contains a monoclonal antibody called trastuzumab that binds to a protein called HER2, which is found on some breast cancer cells. It also contains an anticancer drug called DM1, which may help kill cancer cells. T-DM1 is a type of antibody-drug conjugate. Also called ado-trastuzumab emtansine and Kadcyla.
What is T-DM1 in breast cancer?
Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) is a targeted therapy approved by the U.S. Food and Drug Administration (FDA) to treat: HER2-positive metastatic breast cancer that has previously been treated with Herceptin (chemical name: trastuzumab) and taxane chemotherapy.
How effective is T-DM1?
The researchers who led the trial estimated that, at 3 years after beginning adjuvant treatment, 88% of women treated with T-DM1 were alive and free of invasive cancer, compared with 77% of women treated with trastuzumab.
How do you pronounce Kadcyla?
Trastuzumab emtansine is a type of targeted cancer drug. It is also known by its brand name Kadcyla and TDM1. breast cancer. Trastuzumab emtansine is pronounced trast-oo-zoo-mab em-tan-seen.
Does Emtansine cause hair loss?
It is an ADC, and the emtansine, which is the chemotherapy is cleaved and most of it stays inside the tumor cell. It doesn’t cause hair loss.
Does emtansine cause hair loss?
What are the side effects of Kadcyla?
What are the most common side effects of KADCYLA?
- Tiredness.
- Nausea.
- Liver problems.
- Pain that affects the bones, muscles, ligaments, and tendons.
- Bleeding.
- Low platelet count.
- Headache.
- Weakness, numbness, and pain in the hands and feet.
What is Emtansine?
Ado-trastuzumab emtansine injection is used to treat a certain type of breast cancer that has spread to other parts of the body and has not improved or has worsened after treatment with other medications.
